PriceTargets.com logo

DermTech - DMTK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.07
  • Forecasted Upside: ∞
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 06/26/2024 09:59 PM ET
+0 (0.00%)
Get New DermTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMTK

Analyst Price Target is $1.07
▲ +∞ Upside Potential
This price target is based on 3 analysts offering 12 month price targets for DermTech in the last 3 months. The average price target is $1.07, with a high forecast of $1.50 and a low forecast of $0.63. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for DMTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in DermTech. This rating has held steady since April 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/11/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/19/2024Lake Street CapitalReiterated RatingBuy ➝ Hold$0.63
4/19/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$1.50
4/19/2024BTIG ResearchReiterated RatingBuy ➝ Neutral
3/5/2024StephensLower TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.50
8/7/2023BTIG ResearchLower TargetBuy ➝ Buy$6.00 ➝ $5.00
3/29/2023TD CowenLower TargetOutperform$8.00 ➝ $6.00
11/9/2022StephensLower TargetOverweight$16.00 ➝ $5.00
11/8/2022BTIG ResearchLower TargetBuy$15.00 ➝ $6.00
11/7/2022CowenLower Target$20.00 ➝ $8.00
11/7/2022CowenLower Target$20.00 ➝ $8.00
11/4/2022Lake Street CapitalLower Target$14.00 ➝ $6.00
11/4/2022William BlairDowngradeOutperform ➝ Market Perform
8/17/2022OppenheimerLower TargetOutperform$48.00 ➝ $23.00
8/15/2022BTIG ResearchLower TargetBuy$19.00 ➝ $15.00
8/9/2022Lake Street CapitalLower Target$34.00 ➝ $14.00
8/9/2022Craig HallumLower Target$37.00 ➝ $18.00
7/18/2022OppenheimerReiterated RatingOutperform$48.00
6/14/2022BTIG ResearchLower TargetBuy$38.00 ➝ $19.00
5/4/2022CowenLower Target$33.00 ➝ $20.00
4/14/2022BTIG ResearchReiterated RatingBuy$48.00 ➝ $38.00
3/2/2022Lake Street CapitalLower Target$79.00 ➝ $34.00
3/2/2022Craig HallumLower Target$50.00 ➝ $37.00
1/7/2022StephensInitiated CoverageOverweight$26.00
11/21/2021BTIG ResearchLower TargetBuy$53.00 ➝ $48.00
11/10/2021Craig HallumLower TargetBuy ➝ In-Line$70.00 ➝ $50.00
5/14/2021OppenheimerReiterated RatingBuy$58.00
5/3/2021BTIG ResearchInitiated CoverageBuy$53.00
3/5/2021Craig HallumBoost TargetBuy$49.00 ➝ $70.00
3/4/2021OppenheimerReiterated RatingBuy$58.00
2/11/2021Lake Street CapitalBoost TargetBuy$52.00 ➝ $79.00
1/21/2021OppenheimerInitiated CoverageOutperform$53.00
1/20/2021Craig HallumBoost TargetBuy$23.00 ➝ $49.00
12/14/2020Craig HallumInitiated CoverageBuy$23.00
10/29/2020William BlairInitiated CoverageOutperform
9/11/2020Brookline Capital ManagementInitiated CoverageBuy
9/10/2020CowenInitiated CoverageOutperform$20.00
5/1/2020Lake Street CapitalReiterated RatingBuy$24.00
3/17/2020Lake Street CapitalReiterated RatingBuy$15.00 ➝ $24.00
3/11/2020Lake Street CapitalBoost TargetBuy$15.00 ➝ $24.00
12/5/2019Lake Street CapitalInitiated CoverageBuy$15.00
(Data available from 10/6/2019 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/8/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
DermTech logo
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.19
Low: $0.05
High: $0.42

52 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

Frequently Asked Questions

What sell-side analysts currently cover shares of DermTech?

The following Wall Street research analysts have issued research reports on DermTech in the last twelve months: BTIG Research, Lake Street Capital, and Stephens.
View the latest analyst ratings for DMTK.

What is the current price target for DermTech?

2 Wall Street analysts have set twelve-month price targets for DermTech in the last year. Their average twelve-month price target is $1.07. Stephens has the highest price target set, predicting DMTK will reach $1.50 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $0.63 for DermTech in the next year.
View the latest price targets for DMTK.

What is the current consensus analyst rating for DermTech?

DermTech currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DMTK, but not buy more shares or sell existing shares.
View the latest ratings for DMTK.

What other companies compete with DermTech?

Other companies that are similar to DermTech include BioRestorative Therapies, BioNexus Gene Lab, Centogene, CareMax and Marpai. Learn More about companies similar to DermTech.

How do I contact DermTech's investor relations team?

DermTech's physical mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company's listed phone number is (858) 450-4222 and its investor relations email address is [email protected]. The official website for DermTech is www.dermtech.com. Learn More about contacing DermTech investor relations.